Susquehanna International Group
LTRN icon

Susquehanna International Group’s Lantern Pharma LTRN Stock Holding History

Susquehanna International Group’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-104,000
Closed -$915K – 12744
2024
Q1 		$915K Buy
+104,000
New +$556K ﹤0.01% 7120
2021
Q2 		– Sell
-17,900
Closed -$325K – 12966
2021
Q1 		$325K Buy
+17,900
New +$314K ﹤0.01% 10436

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group's LTRN Position: Q1 2026 in Review

Susquehanna International Group sold out of Lantern Pharma (LTRN) in Q1 2026, closing a stake of 28,820 shares — an estimated $87.3K sold.

Susquehanna International Group first reported a position in LTRN in Q3 2021 and held it in 11 quarters. The position peaked at $279K in Q2 2024. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Susquehanna International Group reported no remaining Lantern Pharma position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 28,820 Lantern Pharma shares in Q1 2026, an estimated $87.3K.
  • Susquehanna International Group first reported a position in Lantern Pharma in Q3 2021 and held it in 11 quarters.
  • Susquehanna International Group's Lantern Pharma position peaked at $279K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.